Categories: NewsPharmaceutical

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid’s senior management will discuss financial results for the quarter and fiscal year ended April 30, 2024, and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

CONTACT: Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com

Staff

Recent Posts

Ascentiz Unveiled Modular Designed Exoskeleton at CES 2026: A Technical Deep Dive into Biomechanical Intelligence

The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…

10 hours ago

From Clinical Recovery to Lifelong Empowerment: RoboCT Showcases Integrated Ecosystem Strategy at CES 2026

Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…

10 hours ago

Nanodropper® Now Operating as Mu Medical™, Planned Expansion of Precision Eyecare Platform with Bedo Solutions and Viseon Labs

The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…

10 hours ago

Flo Health’s App Wins Google Play “Best of 2025” Award for Best for Watches in Hong Kong, Taiwan, and Macau

LONDON, Jan. 9, 2026 /PRNewswire/ -- Flo Health, the company behind the globally trusted Flo…

10 hours ago

Gifthealth Celebrates Grand Opening Of New Pharmacy In Mesa

MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…

10 hours ago

Lucent Health Names Aadam Hussain as Chief Executive Officer Following Brett Rodewald’s Retirement

NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…

10 hours ago